In December 2024, GP2 announced the 9th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 17,690 additional genotyped participants. The genotype array data, including locally-restricted samples, now consists of a total of 71,835 genotyped participants (31,985 PD cases, 18,249 Controls, and 21,601 ‘Other’ phenotypes) When removing the locally-restricted samples, these now consist of 55,305 samples (23,709 PD cases, 13,404 Controls, and 18,192 ‘Other’ phenotypes) Of those 71,835 samples with genotyped data: 16,800 individuals also have deep clinical phenotyping information (Release 8) 10,454 total individuals also have clinical exomes information (Release 8) 7,732 total individuals also have WGS data (Release 8) Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.14510099, release 9) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org."